Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF) has appointed Giles Moss, formerly a senior executive at GW Pharmaceuticals, as an advisor to the company, supporting licensing strategy, capital markets and regulatory matters.
Moss was general manager for Europe when GW was acquired by Jazz Pharmaceuticals for $7.2 billion.
"We are honoured to have Giles join us. His input will help us achieve our ambition of getting a regulatory-approved CBD drug to market faster and at a lower cost than would otherwise be the case," said chief executive Melissa Sturgess.
"We have now recruited two ex-GW leaders to our team, both are on track to increasing their roles and their remuneration is aligned with shareholders' interests - we take all three points as significant endorsements of Ananda's strategy and outlook."
Moss, meanwhile, added: "There remains genuine unfinished business in the cannabinoid space due to the very limited therapeutic access to potentially life changing medicines. Demand from both physicians and patients for regulatory-approved CBD therapeutics continues.
"The time is ripe to lead the way in developing the next generation of cannabis derived, regulatory-approved medicines and I am very much looking forward to supporting Ananda on the journey."